Advances in the pharmacotherapeutic management of refractory peptic ulcers

References

• Lanas A, Chan FKL Peptic ulcer disease. Lancet. 2017 Aug 5;390(10094):613–624. DOI:10.1016/S0140-6736(16)32404-7
   PubMedGoogle Scholar
• Wong GL, Wong VW, Chan Y, et al. High incidence of mortality and recurrent bleeding in patients with helicobacter pylori–negative idiopathic bleeding ulcers. Gastroenterology. 2009;137(2):525–531. DOI:10.1053/j.gastro.2009.05.006
   PubMedGoogle Scholar
• Charpignon C, Lesgourgues B, Pariente A, et al. Peptic ulcer disease: one in five is related to neither Helicobacter pylori nor aspirin/NSAID intake. Aliment Pharmacol Ther. 2013;38(8):946–954. DOI:10.1111/apt.12465
   PubMed Web of Science ®Google Scholar
• Hung LC, Ching JY, Sung JJY, et al. Long-term outcome of helicobacter pylori–negative idiopathic bleeding ulcers: a prospective cohort study. Gastroenterology. 2005 Jun;128(7):1845–1850. DOI:10.1053/j.gastro.2005.03.026
   PubMedGoogle Scholar
• Lau JY, Barkun A, Fan D-M, et al. Challenges in the management of acute peptic ulcer bleeding. Lancet. 2013 Jun 8;381(9882):2033–2043. DOI:10.1016/S0140-6736(13)60596-6
   PubMedGoogle Scholar
• Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151(1):51–69. DOI:10.1053/j.gastro.2016.04.006
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, Rokkas, T. et al. Management of helicobacter pylori infection: the maastricht VI/Florence consensus report. Gut. 2022;71:1724–1762. DOI:10.1136/gutjnl-2022-327745
   Web of Science ®Google Scholar
• Gurusamy KS, Pallari E Medical versus surgical treatment for refractory or recurrent peptic ulcer, Cochrane Database Syst Rev. 2016 Mar 29; 3(3). DOI:10.1002/14651858.CD011523.pub2
   Google Scholar
• Kanno T, Iijima K, Abe, Y. et al. Helicobacter pylori-negative and non-steroidal anti- inflammatory drugs-negative idiopathic peptic ulcers show refractoriness and high recurrence incidence: multicenter follow-up study of peptic ulcers in Japan. Digestive Endoscopy. 2016;28(5):556–563. DOI:10.1111/den.12635
   PubMedGoogle Scholar
• Goldstein JL, Johanson JF, HAWKEY CJ, et al. Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy – a randomized study comparing ranitidine with esomeprazole. Aliment Pharmacol Ther. 2007;26(8):1101–1111. DOI:10.1111/j.1365-2036.2007.03460.x
   PubMedGoogle Scholar
• Lanas A. NSAID use and abuse in gastroenterology: refractory peptic ulcers. Acta Gastroenterol Belg. 1999 Oct;62(4):418–420.
   PubMedGoogle Scholar
• Lanas A, Remacha B, Esteva F, et al. Risk factors associated with refractory peptic ulcers. Gastroenterology. 1995 Oct; 109(4): 1124–1133. DOI:10.1016/0016-5085(95)90570-7
   PubMedGoogle Scholar
• Kim HU. Diagnostic and treatment approaches for refractory peptic ulcers. Clin Endosc. 2015 Jul;48(4):285–290.
   PubMedGoogle Scholar
• Parasher G, Eastwood GL. Smoking and peptic ulcer in the Helicobacter pylori era. Eur J Gas-Troenterol Hepatol. 2000 Aug;12(8):843–853.
   PubMedGoogle Scholar
• Gonzalez-Perez A, Saez ME, Johansson S, et al. Risk factors associated with uncomplicated peptic ulcer and changes in medication use after diagnosis. PLoS ONE 2014 Jul8;9(7). e101768. DOI:10.1371/journal.pone.0101768
   PubMedGoogle Scholar
• Lanas A, Remacha B, Sáinz R, et al. Study of outcome after targeted intervention for peptic ulcer resistant to acid suppression therapy. Am J Gastroenterol. 2000 Feb;95(2):513–519. DOI:10.1111/j.1572-0241.2000.01777.x
   PubMedGoogle Scholar
• Phan J, Benhammou JN, Pisegna JR. Gastric hypersecretory states: investigation and management. Curr Treat Options Gastroenterol. 2015 Dec;13(4):386–397.
   PubMedGoogle Scholar
• Hirschowitz BI, Lanas A. Atypical and aggressive upper gastrointestinal ulceration associated with aspirin abuse. J Clin Gastroenterol. 2002 May;34(5):523–528.
   PubMedGoogle Scholar
• Lau JY, Sung J, Hill, C. et al. Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality. Digestion. 2011;84(2):102–113. DOI:10.1159/000323958
   PubMed Web of Science ®Google Scholar
• Wong GL, Au KW, Lo AO, et al. Gastroprotective therapy does not improve outcomes of patients with helicobacter pylori–negative idiopathic bleeding ulcers. Clin Gastroenterol Hepatol. 2012;10(10):1124–1129. DOI:10.1016/j.cgh.2012.06.012
   PubMedGoogle Scholar
• Calvet X, Gomollón F What is potent acid inhibition, and how can it be achieved drugs.2005;651:13–23. DOI:10.2165/00003495-200565001-00004
   Google Scholar
• Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors emphasis on rabeprazole. Aliment Pharmacol Ther. 1999;13 Suppl. 3:27–36.
   PubMed Web of Science ®Google Scholar
• Verdu EF, Armstrong D, Idström J-P, et al. Intragastric pH during treatment with omeprazole: role of Helicobacter pylori and H. pylori-associated gastritis. Scand J Gastroenterol. 1996;31(12):1151–1156. DOI:10.3109/00365529609036903
   PubMed Web of Science ®Google Scholar
• Labenz J, Tillenburg B, Peitz, U. et al. Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer. Gut. 1997;41:33–36.
   PubMedGoogle Scholar
• Iijima K, Koike T, Abe Y, et al. Time series analysis of gastric acid secretion over a 20-year period in normal Japanese men. J Gastroenterol. 2015;50(8):853–861. DOI:10.1007/s00535-014-1031-2
   PubMedGoogle Scholar
• Gielisse EA, Kuyvenhoven JP. Follow-up endoscopy for benign- appearing gastric ulcers has no additive value in detecting malignancy: it is time to individualise surveillance endoscopy.Gastric Cancer. Gastric Cancer. 2015;18(4):803–809.
   PubMed Web of Science ®Google Scholar
• National Clinical Guideline Centre. Obesity. Identification, assessment and management of overweight and obesity in children, young people and adults. Available at: http://www.nice.org.uk/guidance/cg189/evidence/obesity-update-full-guideline-1933424292014 (accessed 25 Nov 2015).
   Google Scholar
• Edholm D, Ottosson J, Sundbom M. Importance of pouch size in laparoscopic Roux-en-Y gastric bypass: a cohort study of 14,168 patients. Surg Endosc. 2015;30(5):2011–2015.
   PubMedGoogle Scholar
• Coblijn UK, Goucham AB, Lagarde SM, et al. Development of ulcer disease after Roux-en-Y gastric bypass, incidence, risk factors, and patient presentation: a systematic review. Obes Surg. 2014 Feb; 24(2): 299–309. DOI:10.1007/s11695-013-1118-5
   PubMed Web of Science ®Google Scholar
• Lagoo J, Pappas TN, Perez A. A relic or still relevant: the narrowing role for vagotomy in the treatment of peptic ulcer disease. Am J Surg. 2014;207(1):120–126.
   PubMedGoogle Scholar
• Hirschowitz BI, Lanas A. Intractable upper gastrointestinal ulceration due to aspirin in patients who have undergone surgery for peptic ulcer. Gastroenterology. 1998 May;114(5):883–892.
   PubMedGoogle Scholar
• Kanno T, Iijima K, Abe Y, et al. A multicenter prospective study on the prevalence of Helicobacter pylori -negative and nonsteroidal anti-inflammatory drugs-negative idiopathic peptic ulcers in Japan. J Gastroenterol Hepatol. 2015;30(5):842–848. DOI:10.1111/jgh.12876
   PubMedGoogle Scholar
• Murakami K, Sakurai Y, Shiino, M. et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016 Sep;65(9):1439–1446. DOI:10.1136/gutjnl-2015-311304
   PubMed Web of Science ®Google Scholar
• Sugawara K, Koizumi S, Horikawa Y, et al. Is the new potent acid-inhibitory drug vonoprazan effective for healing idiopathic peptic ulcers? A multicenter observational study in Akita Prefecture, Japan. J Gastroenterol. 2019;54(11):963–971. DOI:10.1007/s00535-019-01587-5
   PubMed Web of Science ®Google Scholar
• Serafim C, Araruna ME, Júnior EA, et al. A review of the role of flavonoids in peptic ulcer (2010–2020). Molecules. 2020 Nov 20; 25 (22): 5431. DOI:10.3390/molecules25225431
   PubMedGoogle Scholar
• Périco LL, Emílio-Silva MT, Ohara, R. et al. Systematic analysis of monoterpenes: advances and challenges in the treatment of peptic ulcer diseases. Biomolecules. 2020 Feb 10;10(2):265. DOI:10.3390/biom10020265
   PubMedGoogle Scholar
• Rostami H, Haddadi MH. Benzimidazole derivatives: a versatile scaffold for drug development against Helicobacter pylori-related diseases. Fundam Clin Pharmacol. 2022 Dec;36(6):930–943.
   PubMedGoogle Scholar
• Saleh M, Sohrabpour AA, Mehrabi, M.R. et al. Therapeutic approach of adipose-derived mesenchymal stem cells in refractory peptic ulcer. Stem Cell Res Ther. 2021 Sep 26;12(1):515. .
   PubMedGoogle Scholar
• Tarnawski AS, Ahluwalia A. Molecular mechanisms of epithelial regeneration and neovascularization during healing of gastric and esophageal ulcers. Curr Med Chem. 2012;19(1):16.27.
   Google Scholar
• Chamberlain G, Fox J, Ashton, B. et al. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. StemCells. 2007;25(11):2739–2749.
   Google Scholar
• Shäffler A, Büchler C Concise review: adipose tissue-derived stromal cells—basic and clinical implications for novel cell-based therapies. Stem Cells. 2007;25(4):818–827. DOI:10.1634/stemcells.2006-0589
   PubMedGoogle Scholar
• Bardhan KD. Refractory duodenal ulcer. Gut. 1984 Jul;25(7):711–717.
   PubMed Web of Science ®Google Scholar
• Bardhan KD, Royston C. Time, change and peptic ulcer disease in Rotherham, UK. Dig Liver Dis. 2008 Jul;40(7):540–546.
   PubMedGoogle Scholar
• Scheiman JM, Devereaux PJ, Herlitz, J. et al. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart. 2011 May;97(10):797–802. DOI:10.1136/hrt.2010.217547
   PubMed Web of Science ®Google Scholar
• Clapp B, Hahn J, Dodoo C, et al. Evaluation of the rate of marginal ulcer formation after bariatric surgery using the MBSAQIP database. Surg Endosc. 2019 Jun;33(6):1890–1897. DOI:10.1007/s00464-018-6468-6
   PubMedGoogle Scholar
• Martino BR, Manibusan P Zollinger ellison syndrome refractory to medical therapy in the setting of multiple endocrine neoplasia type I. Cureus. 2022 Jun 30;14(6):e26468. DOI:10.7759/cureus.26468
   PubMedGoogle Scholar
• Poitras P, Gingras MH, Rehfeld JF. The zollinger–ellison syndrome: dangers and consequences of interrupting antisecretory treatment. Clin Gastroenterol Hepatol. 2012 Feb;10(2):199–202.
   PubMed Web of Science ®Google Scholar
• Dean L, Kane M Omeprazole therapy and CYP2C19 Genotype. 2012 Oct 1 [updated 2021 Feb 4]. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kane MS, Kattman BL, Malheiro A, editor. Medical genetics summaries [internet]. Bethesda (MD): National Center forBiote-chnology Information (US); 2012. https://www.ncbi.nlm.nih.gov/books/NBK100895/
   Google Scholar
• Xu T, Tian Y, Wang Y, et al. Effects of autologous platelet-rich plasma on healing of peptic ulcers: a randomized controlled trial. Gastroente-rol Res Pract. 2022 Jul 15; Vol. 2022, p. 7944849. DOI:10.1155/2022/7944849
   Google Scholar